80 completed, 30 unknown, 23 recruiting, 21 terminated. 122 Phase 2, 68 Phase 1, 14 Phase 3, 11 Not applicable, 1 Early Phase 1.
Follow Metastatic Pancreatic Cancer: new trials by email Literature Review of Metastatic Pancreatic Cancer trials Research Report on Metastatic Pancreatic Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC certepetide, nab-paclitaxel, gemcitabine - Pancreas Cancer, Pancreatic Carcinoma | Phase 1 / Phase 2 | Withdrawn | Lisata Therapeutics, Inc. | 2030-01-01 | 2025-06-06 | |
| Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic Cancer Personalized cancer vaccine including : DNA neoantigen vaccine, MVA viral vector and Ipilimumab (anti-CTLA4) - Metastatic Colorectal Cancer (CRC), Locally Advanced Colorectal Cancer | Phase 1 | Not yet recruiting | Centre Georges Francois Leclerc | 77 | 2026-11-01 | 2026-05-14 |
| A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failure of Gemcitabine-Based Systemic Chemotherapy Tambotatug pelitecan, Liposomal irinotecan, 5 Fluorouracil - Metastatic Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 3 | Not yet recruiting | MediLink Therapeutics (Suzhou) Co., Ltd. | 320 | 2026-10-01 | 2026-09-04 |
| GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Locally Advanced or Metastatic PDAC SHR-1701, Apatinib, gemcitabine - Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | Not yet recruiting | West China Hospital | 45 | 2026-09-10 | 2026-09-03 |
| Phase I Open-Label Randomized Multicenter Study of XNW28012 Monotherapy in Metastatic Pancreatic Cancer XNW28012 - Metastatic Pancreatic Cancer | Phase 1 | Not yet recruiting | Evopoint Biosciences Inc. | 24 | 2026-07-30 | 2026-07-22 |
| A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer Setidegrasib, Oxaliplatin, Leucovorin - Pancreatic Cancer, Metastatic Pancreatic Cancer | Phase 3 | Recruiting | Astellas Pharma Global Development, Inc. | 614 | 2026-02-17 | 2026-09-22 |
| Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer Olaptesed pegol, Pembrolizumab - Metastatic Pancreatic Cancer | Phase 2 | Not yet recruiting | TME Pharma AG | 60 | 2026-01-01 | 2025-06-27 |
| The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer Kinisoquin™, Placebo - Venous Thromboembolism, Metastatic Pancreatic Cancer | Phase 3 | Recruiting | Quercis Pharma AG | 480 | 2025-12-19 | 2026-02-02 |
| Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer GFH375, Chemotherapy - Metastatic Pancreatic Cancer | Phase 3 | Recruiting | Genfleet Therapeutics (Shanghai) Inc. | 320 | 2025-12-04 | 2026-08-14 |
| A Phase II Study to Evaluate GFH375 in Patients With KRAS G12D Mutant Metastatic Pancreatic Cancer GFH375 - Metastatic Pancreatic Cancer | Phase 2 | Withdrawn | Genfleet Therapeutics (Shanghai) Inc. | 2025-08-01 | 2025-11-17 | |
| The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation Stereotactic Body Radiation Therapy, Botensilimab, Balstilimab - Metastatic Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Cancer | Phase 2 | Recruiting | Benjamin Spieler | 20 | 2025-06-18 | 2026-08-21 |
| Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT) - Pancreatic Cancer, Pancreatic Adenocarcinoma | Not applicable | Recruiting | Alpha Tau Medical LTD. | 50 | 2025-06-17 | 2026-08-27 |
| QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer QL1706, Chidamide, Gemcitabine - Metastatic Pancreatic Cancer | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 33 | 2025-03-07 | 2026-01-26 |
| Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel Gemcitabine, Nab paclitaxel, Erlotinib - Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 104 | 2025-02-06 | 2026-04-23 |
| A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab Evofosfamide, Zalifrelimab, Balstilimab - Metastatic Prostate Cancer, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | ImmunoGenesis | 71 | 2025-01-08 | 2025-01-21 |
| mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer Anlotinib combined with Sintilimab - Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | Recruiting | Fujian Provincial Hospital | 29 | 2024-12-23 | 2025-01-07 |
| YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer YL-13027, HY-0102, Gemcitabine - Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | Not yet recruiting | Shanghai YingLi Pharmaceutical Co. Ltd. | 120 | 2024-11-30 | 2024-10-29 |
| A Multi-center, Single-arm, Prospective Non-interventional Study to Investigate the Safety Profiles and Effectiveness of Liposomal Irinotecan (ONIVYDE®) in Combination with 5-fluorouracil (5-FU) and Leucovorin (LV) in Chinese Patients with Metastatic Pancreatic Cancer As Approval Condition (SEOPAC) Metastatic Pancreatic Cancer | Not yet recruiting | Servier (Tianjin) Pharmaceutical Co. LTD. | 120 | 2024-11-01 | 2024-11-14 | |
| Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001) anlotinib + benmelstobart + nab-paclitaxel + gemcitabine, nab-paclitaxel + gemcitabine - Pancreatic Cancer, First-line | Phase 2 | Not yet recruiting | RenJi Hospital | 104 | 2024-10-30 | 2024-10-01 |
| A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors ERX-315 - Advanced Solid Tumor, Metastatic Breast Cancer | Phase 1 | Recruiting | EtiraRx Australia Pty Ltd | 36 | 2024-10-14 | 2026-05-29 |
Showing 20 of 198. Sign in to see all of them.
Pancreatic Neoplasms (198) · Neoplasm Metastasis (25) · Neoplasms (16) · Colorectal Neoplasms (13) · Breast Neoplasms (6) · Adenocarcinoma (5) · Carcinoma, Non-Small-Cell Lung (4) · Colonic Neoplasms (4) · Endometrial Neoplasms (4) · Carcinoma, Hepatocellular (3) · Lung Neoplasms (3) · Melanoma (3) · Ovarian Neoplasms (3) · Stomach Neoplasms (3) · Carcinoma, Pancreatic Ductal (2)
Endocrine System Diseases (198) · Digestive System Diseases (197) · Digestive System Neoplasms (197) · Endocrine Gland Neoplasms (197) · Neoplasms by Site (197) · Pancreatic Diseases (196) · Neoplasms (182) · Pathological Conditions, Signs and Symptoms (29) · Neoplastic Processes (27) · Pathologic Processes (27) · Neoplasms by Histologic Type (17) · Gastrointestinal Diseases (16) · Neoplasms, Glandular and Epithelial (16) · Colonic Diseases (15) · Gastrointestinal Neoplasms (15)
Gemcitabine (72) · 130-nm albumin-bound paclitaxel (33) · Albumin-Bound Paclitaxel (26) · Oxaliplatin (17) · Leucovorin (16) · Fluorouracil (15) · Taxes (12) · irinotecan sucrosofate (11) · Irinotecan (9) · Nivolumab (9) · Capecitabine (8) · Erlotinib Hydrochloride (7) · Paclitaxel (6) · folfirinox (6) · pembrolizumab (6)
Fudan University (6) · Georgetown University (5) · Brown University (4) · National Cancer Institute (NCI) (4) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (4) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (3) · Alpha Tau Medical LTD. (3) · Celgene (3) · Eli Lilly and Company (3) · Federation Francophone de Cancerologie Digestive (3) · Memorial Sloan Kettering Cancer Center (3) · Ono Pharmaceutical Co., Ltd. (3) · Tianjin Medical University Cancer Institute and Hospital (3) · AIO-Studien-gGmbH (2) · Acerta Pharma BV (2)
United States (98) · China (21) · France (21) · South Korea (13) · Germany (12) · Spain (12) · Canada (10) · Italy (10) · Japan (9) · Netherlands (7) · Taiwan (7) · Australia (6) · United Kingdom (5) · Austria (4) · Israel (4)
Howard Safran, MD (3) · Project Leader (3) · Xian-Jun Yu (3) · Andrea Enzinger, MD (2) · Daniel Von Hoff, MD (2) · Dung Le, MD (2) · Michael Pishvaian, MD PhD (2) · Udo Rudloff, M.D. (2) · A. James Moser, MD (1) · Aaron Scott, MD (1) · Ana De Jesus-Acosta, MD (1) · Andrew Dean (1)
PMID 19826418, PMID 21629990, PMID 22162229, PMID 22272248, PMID 22302349, PMID 24131140, PMID 24812403, PMID 25398812, PMID 25638248, PMID 26046796, PMID 26067687, PMID 26187510, PMID 26372701, PMID 26445094, PMID 26458923, PMID 26615328, PMID 26655559, PMID 26802153, PMID 26802160, PMID 27022826, PMID 28222309, PMID 28388966, PMID 28397697, PMID 28774338, PMID 29158367, PMID 29232172, PMID 30414528, PMID 30654298, PMID 30714987, PMID 30842038, PMID 31065624, PMID 31068222, PMID 31789476, PMID 31856081, PMID 31857726, PMID 32114502, PMID 32361265, PMID 32523632, PMID 32623182, PMID 32672806, PMID 33015088, PMID 33038277, PMID 33214082, PMID 33296830, PMID 33345430, PMID 33478521, PMID 33688022, PMID 34288696, PMID 34895986, PMID 35104158
2014 (2), 2015 (2), 2016 (2), 2017 (2), P01CA247886 (2), 1UG1CA189823-01 (1), 2018 (1), 2023 (1), 2025 (1), U54CA156732 (1)